CN104055773B - 一种降血脂组合物及其应用 - Google Patents
一种降血脂组合物及其应用 Download PDFInfo
- Publication number
- CN104055773B CN104055773B CN201410315242.XA CN201410315242A CN104055773B CN 104055773 B CN104055773 B CN 104055773B CN 201410315242 A CN201410315242 A CN 201410315242A CN 104055773 B CN104055773 B CN 104055773B
- Authority
- CN
- China
- Prior art keywords
- ornithine
- acid
- component
- weight ratio
- following weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 89
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 66
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract description 48
- 229960003104 ornithine Drugs 0.000 claims abstract description 48
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims abstract description 47
- 210000004369 blood Anatomy 0.000 claims abstract description 18
- 239000008280 blood Substances 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 17
- 230000036541 health Effects 0.000 claims abstract description 12
- 235000013373 food additive Nutrition 0.000 claims abstract description 5
- 239000002778 food additive Substances 0.000 claims abstract description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 22
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 22
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 18
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 11
- 229960002685 biotin Drugs 0.000 claims description 11
- 235000020958 biotin Nutrition 0.000 claims description 11
- 239000011616 biotin Substances 0.000 claims description 11
- 235000019161 pantothenic acid Nutrition 0.000 claims description 11
- 229940055726 pantothenic acid Drugs 0.000 claims description 11
- 239000011713 pantothenic acid Substances 0.000 claims description 11
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 10
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 10
- 229960005261 aspartic acid Drugs 0.000 claims description 10
- 229960000304 folic acid Drugs 0.000 claims description 10
- 235000019152 folic acid Nutrition 0.000 claims description 10
- 239000011724 folic acid Substances 0.000 claims description 10
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 claims description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 9
- 229930003268 Vitamin C Natural products 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 5
- 235000008151 pyridoxamine Nutrition 0.000 claims description 5
- 239000011699 pyridoxamine Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 abstract description 26
- 210000004185 liver Anatomy 0.000 abstract description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 16
- 108090000790 Enzymes Proteins 0.000 abstract description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 7
- 235000012000 cholesterol Nutrition 0.000 abstract description 6
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 abstract description 2
- 108010082126 Alanine transaminase Proteins 0.000 abstract description 2
- 230000036770 blood supply Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000004129 fatty acid metabolism Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 15
- 108010023302 HDL Cholesterol Proteins 0.000 description 12
- 108010028554 LDL Cholesterol Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 10
- 238000005469 granulation Methods 0.000 description 10
- 230000003179 granulation Effects 0.000 description 10
- 210000005229 liver cell Anatomy 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 description 7
- 239000011122 softwood Substances 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000005515 coenzyme Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 230000004143 urea cycle Effects 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- -1 antibody Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229960002662 propylthiouracil Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 229940048102 triphosphoric acid Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- 208000029751 Amino acid metabolism disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 101001074429 Bacillus subtilis (strain 168) Polyketide biosynthesis acyltransferase homolog PksD Proteins 0.000 description 1
- 101000936617 Bacillus velezensis (strain DSM 23117 / BGSC 10A6 / FZB42) Polyketide biosynthesis acyltransferase homolog BaeD Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 150000008537 L-aspartic acids Chemical class 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000031016 anaphase Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229940089653 folic acid 0.3 mg Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940089807 pantothenic acid 5 mg Drugs 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000014612 sandwich biscuits Nutrition 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/24—Organic nitrogen compounds
- A21D2/245—Amino acids, nucleic acids
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/30—Organic phosphorus compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于保健品、食品及医药技术领域，公开了一种降血脂组合物及其应用。该组合物含有鸟氨酸、门冬氨酸、维生素B6。该降血脂组合物能够调节血脂、保肝护肝、增强心脑血管供血能力、降低甘油三酯、胆固醇及提高谷丙转氨酶、谷草转氨酶的酶活，促进脂肪酸代谢，恢复机体的降血脂能力，可用于制备降血脂的药物、保健品、食品添加剂或者食品。
Description
技术领域
本发明属于保健品、食品及医药技术领域，具体涉及一种降血脂组合物及其应用。
背景技术
高脂血症是指脂肪代谢或运转异常使血浆一种或多种脂质高于正常。它是一种全身性疾病，血总胆固醇(TC)和(或)甘油三酯过高或高密度脂蛋白胆固醇(HDL-C)过低，现代医学称之为血脂异常，也常称为高脂蛋白血症。高脂血症初期多数没有任何症状，若没有及时的纠正，会对身体产生逐渐进行性的全身性的损害。它会加速全身动脉粥样硬化，继而引起肾功能衰竭。目前资料研究表明，高血脂症能使人诱发以下疾病：冠心病、心肌梗死、心脏猝死、脑卒中、高血压、糖尿病、脂肪肝、肝硬化、胆石症、胰腺炎、高尿酸血症等。
氨基酸是构成生物体蛋白质并同生命活动有关的最基本的物质，是在生物体内构成蛋白质分子的基本单位，与生物的生命活动有着密切的关系。它在抗体内具有特殊的生理功能，是生物体内不可缺少的营养成分之一。其在人体内通过代谢可以发挥下列一些作用：①合成组织蛋白质；②变成酸、激素、抗体、肌酸等含氨物质；③转变为碳水化合物和脂肪；④氧化成二氧化碳和水及尿素，产生能量。鸟氨酸是非蛋白氨基酸，能激活尿素合成的关键酶-鸟氨酸氨基甲酰转移酶和氨基甲酰磷酸合成酶，提供反应底物鸟氨酸，通过肝脏鸟氨酸循环加速尿素合成，促进氨的代谢，从而达到对血氨的解毒作用。门冬氨酸首先能直接参与尿素循环并参与三磷酸循环及肝细胞内核酸的合成，有利于修复被损伤的肝细胞。此外，由于门冬氨酸对肝细胞内三羧酸循环代谢过程的间接促进作用，并提供能量代谢的中间产物，促进了肝细胞的能量生成，使被损伤的肝细胞的各项功能得以迅速恢复。
B族维生素是水溶性维生素，包括维生素B1、维生素B2、维生素B6、维生素B12、烟酸、泛酸、叶酸等，是推动体内代谢，把糖、脂肪、蛋白质等转化成热量时不可缺少的物质。它们具有协同作用，调节新陈代谢，增进免疫系统促进细胞生长和分裂。B6可能是所有维生素B族中最重要的一种。人体的肌肉里含有全身70％～80％的B6。B6在蛋白、脂质和碳水化合物的代谢中发挥着关键的作用。所以，大量损耗B6的人会出现包括氨基酸代谢紊乱。维生素B6是氨基酸的代谢与合成的重要辅酶，并参与不饱和脂肪酸的代谢等生理过程，是机体内许多重要酶系统的辅酶，是动物正常发育、细菌和酵母繁殖所必需的营养成分。另外，维生素B6还是一种天然的利尿剂，利尿就能解毒，静脉输入维生素B65g，大约能利出尿液380ml左右。维生素B6是人体氨基酸代谢、神经递质γ-氨基丁酸(GABA)和谷氨酸(Glu)的辅酶，现已知肝脏有60多种酶需要维生素B6参与，在促进机体正常酶代谢方面起到十分重要的作用，且维生素B6在体内的半衰期短，很快就排出体外。
众所周知，肝脏在脂类的消化、吸收、分解、合成和运输等代谢过程中均起很重要的作用。脂类的改造、合成、分解、酮体生成、脂蛋白代谢等等都在肝脏中进行。肝脏能分泌胆汁，胆汁中的胆汁酸盐能促进脂类的消化和吸收。从消化道吸收的甘油三脂在肝细胞没进行同化，运至脂肪组织内储存；饥饿时，储存的脂肪被动员到肝脏及其他组织进行分解代谢。在肝脏内，脂肪酸的β-氧化特别活跃，产生大量的乙酰辅酶A(HMG-CoA)，并将HMG-CoA迅速分解为酮体。并且脂类的运输及其转化均与肝脏功能有着密切关系。如血浆中的极低密度脂蛋白(VLDL)，主要在肝脏内合成，它在血浆中转化为低密度脂蛋白(LDL)，并释放出部分高密度脂蛋白(HDL)，而催化这些转变的一个重要酶-卵磷脂胆固醇转酰酶(LCAT)，也是在肝细胞内合成的。如果以上的代谢反应受到阻碍，肝中脂类的含量就会发生变动，当脂肪在肝中过量存积就会引发脂肪肝。慢性的脂肪肝会引起肝细胞纤维性病变，造成肝硬化，损害肝细胞的正常功能。脂肪肝的发生原理主要是由于输入肝脏的脂肪和脂肪酸过多及肝脏中血浆脂蛋白的合成代谢障碍。
现在社会，随着人们生活水平的提高以及饮食结构的改变，高脂血症患病率在全世界范围内呈不断上升的趋势。至今针对高血脂症治疗的药物有许多，多数是化学合成的化学药品或由某些中药组成的中药复方。化学合成药因其制作工艺，其中存在少量有害物质，长期使用会出现毒性，且后期效果不是很理想；中药复方制剂，因其药效缓和，用药时间长。因此开发出新型的、有效的降血脂的药物或保健产品减低血脂浓度对人体的健康危害是非常有必要的。
发明内容
本发明的目的是针对上述技术问题提供一种降血脂组合物。该降血脂组合物是为高血脂症疾病患者设计的一种复方氨基酸和维生素的组合物，能有效降低血脂浓度，唤醒患者机体本身降血脂能力。
本发明还有一个目的是提供上述降血脂组合物的应用。
本发明的目的是通过下列技术方案实现的：
一种降血脂组合物，该组合物含有鸟氨酸、门冬氨酸和维生素B6。
所述的组合物含有下列重量比的组分：鸟氨酸：门冬氨酸：VB6＝1：0.1～1.2：0.2～1.5，优选鸟氨酸：门冬氨酸：VB6＝1：0.3～0.7：0.4～0.8，进一步优选鸟氨酸：门冬氨酸：VB6＝1：0.5：0.6。
所述的组合物还含有以下辅助成分中的一种或几种：维生素C、枸橼酸、泛酸、生物素、叶酸。
其中辅助成分的用量按重量比计分别为：
鸟氨酸：VC＝1：0.05～1.2，优选鸟氨酸：VC＝1：0.2～0.8，进一步优选鸟氨酸：VC＝1：0.5；
鸟氨酸：枸橼酸＝1：0.001～0.05，优选鸟氨酸：枸橼酸＝1：0.001～0.03，进一步优选鸟氨酸：枸橼酸＝1：0.01；
鸟氨酸：泛酸＝1：0.00001～0.001，优选鸟氨酸：泛酸＝1：0.00005～0.0008，进一步优选鸟氨酸：泛酸＝1：0.0005；
鸟氨酸：生物素＝1：0.000001～0.0005，优选鸟氨酸：生物素＝1：0.000001～0.0001，进一步优选鸟氨酸：生物素＝1：0.000003；
鸟氨酸：叶酸＝1：0.000001～0.0005，优选鸟氨酸：叶酸＝1：0.000003～0.0001，进一步优选鸟氨酸：叶酸＝1：0.00005。
所述的组合物，其中鸟氨酸是指L-鸟氨酸、D-鸟氨酸或者DL-鸟氨酸；门冬氨酸是指L-门冬氨酸、D-门冬氨酸或者DL-门冬氨酸。
所述组合物为保健品或药物时的剂型为药剂学上允许的任何一种剂型，优选的剂型为：颗粒剂、片剂、胶囊剂、散剂、丸剂、粉剂、酒剂、膏剂、丹剂、冲剂、膜剂、口服液、注射剂。
所述组合物在制备降血脂的保健品、药物、食品或食品添加剂中的应用。
所述的食品添加剂，可以添加应用于各类食品中，例如可以作为烘烤糕点、饮料、黄油奶制品等的添加剂。
本发明技术方案综合利用鸟氨酸、门冬氨酸和维生素B6等物质的作用特点，当鸟氨酸、门冬氨酸和维生素B6的联合使用时，鸟氨酸作为尿素循环的反应底物，迅速激活肝细胞内的尿素循环，使得肝脏内酶代谢逐步恢复，从而使得肝脏的活力得到恢复，起到保肝、护肝的作用。门冬氨酸首先能直接参与尿素循环并参与三磷酸循环及肝细胞内核酸的合成，有利于修复被损伤的肝细胞。此外，门冬氨酸对肝细胞内三羧酸循环代谢过程起着间接促进作用，并提供能量代谢的中间产物，促进了肝细胞的能量生成，使被损伤的肝细胞的各项功能得以迅速恢复。而维生素B6是氨基酸的代谢与合成的重要辅酶，并参与不饱和脂肪酸的代谢等生理过程，是机体内许多重要酶系统的辅酶，是动物正常发育、细菌和酵母繁殖所必需的营养成分。且维生素B6还是一种天然的利尿剂，利尿就能解毒。所以鸟氨酸、门冬氨酸和维生素B6的联合使用，能有效的修复受损的肝细胞，恢复肝功能，唤醒机体本身降血脂能力。三者联合使用产生磷脂酰胆碱，帮助脂肪的乳化；肝脏还能促进胆汁盐的合成，消化大量的甘油三脂。而肝脏不仅是体内合成胆固醇的组要器官，并且由高密度脂蛋白转运入肝的胆固醇也在肝细胞转化和排出。一部分胆固醇直接作为胆汁成分与胆汁盐一起经胆道入肠，此时，还能在维生素B6的作用下，顺利将代谢废弃物排出体外。
本发明组合物的优点在于：
对治疗高脂血症有显著的疗效，与现有的化学合成药和中药复方降血脂的方法比较，本发明所制成的组合物不仅副作用小、疾病不易复发、治疗周期短，而且能为患者提供营养支持、有效的恢复机体本身的降血脂功能、促进酶代谢，达到治标治本的目的。
本发明组合物采用的组分均可来源于食物，安全性高，长期食用无毒副作用，但其各组分的含量比例与食物中的不一致，经实验研究发现，该组合物可发挥一般食物所不具有的降脂作用。
具体实施方式
以下根据实施例进一步具体说明本发明，但本发明不限于以下实施例。
实施例1：作为食品添加剂制作降高血脂夹心饼干
制作工艺如下：
1、将小麦粉、鸡蛋、甜味剂、小苏打、植物油、水按重量配比调制成面团，并放冰箱冷藏松弛1小时后取出擀成2～3mm薄片，用饼干磨具压出形状，一个空心，一个实心，制成饼干外胚。
2、放入烤箱烘烤，冷却，备用。
3、称取适量果酱，以果酱及L-鸟氨酸、L-门冬氨酸及维生素B6的量为总重量100份，按以下重量份数的原料混合均匀：3份L-鸟氨酸、2份L-门冬氨酸、3份维生素B6及92份果酱，制成食品添加剂，抹入饼干空心部位即可。
实施例2：保健口服液制备例
一种降高血脂保健口服液，按下述重量称取各原料：L-鸟氨酸20g、L-门冬氨酸5g、维生素B625g、维生素C15g、木糖醇5g、水20ml，混合均匀，并将混合物罐装到5～50mL瓶中密封，110℃、灭菌20min。
实施例3：药物组合物制备例
一种药物组合物胶囊制剂，其组分为L-鸟氨酸70g，L-门冬氨酸60g，维生素B670g，1％聚乙烯吡咯烷酮乙醇溶液适量，2g硬脂酸镁，共制成800粒。
制备方法：称取L-鸟氨酸、L-门冬氨酸、维生素B6，混合均匀，用1％聚乙烯吡咯烷酮乙醇溶液40mL制成软材，用20目筛制粒，干燥至水分不超过3％，并加入2g硬脂酸镁，混匀，过20目筛整粒，分装，抛光，包装，经过以上工序即得胶囊制剂。
实施例4：药物组合物制备例
一种药物组合物片剂，其组分为L-鸟氨酸70g，L-门冬氨酸60g，维生素B670g，1％聚乙烯吡咯烷酮乙醇溶液适量，1g硬脂酸镁，共制成1000片。
制备方法：称取L-鸟氨酸、L-门冬氨酸、维生素B6，混合均匀，用1％聚乙烯吡咯烷酮乙醇溶液20mL制成软材，接着用20目筛制粒，干燥，并加入1g硬脂酸镁混匀，过20目筛整粒，压片，抛光，包装，经过以上工序即得组合物片剂。
实施例5：药物组合物制备例
一种药物组合物，其组分为混合物质注射液250mL含有：L-鸟氨酸6g，L-门冬氨酸4g，维生素B66g，维生素C3.5g，生物素0.1mg加入到250mL5％葡萄糖氯化钠注射液(糖尿病患者采用0.9％氯化钠注射液)中。
实施例6：
一种药物组合物颗粒剂，其组分为L-鸟氨酸为70g，L-门冬氨酸为60g，维生素B670g，枸橼酸0.5g，泛酸5mg，生物素0.2mg，叶酸0.3mg，维生素C15g。20％乙醇溶液适量为湿润剂，制成颗粒剂。
制备方法：称取上述组分，混合均匀，加入20％乙醇溶液40ml制成软材，挤出滚圆法制成颗粒，干燥至水分不超过3％，即可。
实施例7：
一种药物组合物颗粒剂，其组分为L-鸟氨酸为70g，D-门冬氨酸为60g，维生素B670g，枸橼酸0.5g，生物素0.2mg，维生素C20g。20％乙醇溶液适量为湿润剂，制成颗粒剂。
制备方法：称取上述组分，混合均匀，加入20％乙醇溶液40ml制成软材，挤出滚圆法制成颗粒，干燥至水分不超过3％，即可。
实施例8：
一种药物组合物颗粒剂，其组分为DL-鸟氨酸为70g，L-门冬氨酸为50g，维生素B660g，泛酸30mg，生物素0.5mg，维生素C20g。20％乙醇溶液适量为湿润剂，制成颗粒剂。
制备方法：称取上述组分，混合均匀，加入20％乙醇溶液40ml制成软材，挤出滚圆法制成颗粒，干燥至水分不超过3％，即可。
实施例9：
一种药物组合物颗粒剂，其组分为L-鸟氨酸为70g，DL-门冬氨酸为50g，维生素B660g，泛酸30mg，叶酸3mg，维生素C5g。20％乙醇溶液适量为湿润剂，制成颗粒剂。
制备方法：称取上述组分，混合均匀，加入20％乙醇溶液40ml制成软材，挤出滚圆法制成颗粒，干燥至水分不超过3％，即可。
实施例10：
一种药物组合物颗粒剂，其组分为L-鸟氨酸为70g，DL-门冬氨酸为50g，维生素B635g，维生素C45g。20％乙醇溶液适量为湿润剂，制成颗粒剂。
制备方法：称取上述组分，混合均匀，加入20％乙醇溶液40ml制成软材，挤出滚圆法制成颗粒，干燥至水分不超过3％，即可。
实施例11：本发明组合物的降血脂动物实验
1、实验材料：健康SD清洁级大鼠150只，体重(150.2±8.9)g雌雄兼用。
2、饲料：普通饲料，高脂饲料配方为：基础饲料72.7％、胆固醇2％、蛋黄粉5％、猪油10％、丙硫氧嘧啶0.2％、蔗糖10％、胆酸钠0.1％。
3、动物分组与给药：购入的实验大鼠在实验室适应饲养1周，按称重顺序编原始号，查随机数字表随机分成空白对照组、模型对照组、药物组合物(分别按实施例3、6、8、10制备，每10g加水50ml溶解，配成溶液)低剂量组(5ml/kg·d)，中剂量组(10ml/kg·d)，高剂量组(15ml/kg·d)，阳性药物(辛伐他汀)对照组(1.5mg/kg，容积为10ml/kg)，每组10只。从实验之日起空白对照组、模型对照组灌胃生理盐水(容积为10ml/kg)，给药组灌胃相应药物，1次/d，每周称1次体重，根据体重调整给药量。空白对照组喂饲普通饲料，其余各组喂饲高脂饲料，试验期间自由摄食、自由饮水，连续造模并预防给药4周。
4、观测指标：末次给药后禁食12h，不禁水。3％戊巴比妥钠麻醉大鼠，腹主动脉取血，离心分离血清，测血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、谷丙转氨酶(ALT)、谷草转氨酶(AST)值。
5、结果
a)本发明组合物对大鼠血脂水平的影响
由表1可见，与正常组相比，模型组大鼠血清中TC、TG、LDL-C的水平明显升高(P＜0.05)，呈现典型的脂质代谢紊乱，表明实验性高血脂模型复制成功。与模型组相比，治疗组能明显降低血清TC、TG、LDL-C含量(P＜0.05)，并能显著升高血清HDL-C含量(P＜0.01)且呈现剂量依赖性。
表1各组大鼠血脂变化(n＝10)
b)本发明组合物对大鼠肝功能的影响
血清中ALT和AST可以反应肝脏功能。高脂饲料组ALT和AST明显高于基础饲料组(P<0.01)，说明肝脏有一定损害。而各给药组的血清ALT和AST水平均低于模型对照组，且中剂量、高剂量组与模型对照组比较差异及其显著(P<0.01)，说明本发明组合物在保护肝脏功能方面有显著效果，且对机体有明显的保护作用。
表2各组大鼠肝功能变化情况(n＝10)
高脂血症大鼠灌服本发明组合物后，其TC、TG、LDL-C含量明显降低，而HDL-C含量升高；对高脂饲料造成的血清中ALT和AST的增高有抑制作用。说明本发明组合物促进了脂肪酸代谢，改善肝内脂质代谢，保护肝细胞，有一定的调脂护肝作用，尤其适用于肝功能受损危险度较高的高血脂患者。药理实验证明，本发明中鸟氨酸、门冬氨酸、维生素B6，具有协同作用，可相互增强疗效。
实施例12：本发明组合物在临床治疗中的作用
1、病例选择
将血清总胆固醇(TC)＞5.7mmol/L及(或)甘油三脂(TG)＞1.7mmol/L者选为观察对象，共24例。其中男14例，女10例，年龄26～69岁。
2、诊断标准
参照2010年人民卫生出版社出版的《内科学》，其中有关高血脂的诊断标准，血清总胆固醇(TC)≥5.72mmol/L，甘油三脂(TG)≥1.70mmol/L，低密度脂蛋白胆固醇(LDL-C)≥3.10mmol/L，高密度脂蛋白(HDL-C)男性≤1.04mmol/L，女性≤1.17mmol/L。
3、治疗方法
所有患者在抽血前一天的晚餐禁止饮酒以及近视过量的脂质食品，空腹12小时以上取静脉血，测TC、TG、HDL-C、LDL-C。然后开始服用本发明组合物(按实施例3制备)，每次2粒，每日三次，每粒约含本发明组合物0.25g，连服四周，治疗期间忌食辛辣刺激食物尤其是饮酒。
4、疗效评定标准
显效：治疗后血脂检测达到以下任何一项者，即TC下降≥20％，或者TG下降≥40％，或HDL-C上升≥0.26mmol/L，或HDL-C/LDL-C下降≥20％，或LDL-C下降≥30％。
有效：治疗后血脂检测达到以下任何一项者，即TC下降≥10％但＜20％，或TG下降≥20％但＜40％，或HDL-C上升≥0.14mmol/L但＜0.26mmol/L，或HDL-C/LDL-C下降≥10％但＜20％，或LDL-C下降≥20％。
无效：治疗前后血脂检测物明显改善或改善达不到标准者。
5、治疗效果
24例患者经过两周本发明组合物治疗后，其中显效8例，有效11例，无效5例，无效5例中TC、TG都有不同程度的下降。继续服用本发明组合物两周后，其中显效达到14例，有效9例，无效1例，无效率4.2％，总有效率95.8％。
6、具体病例介绍
(1)高某，男，33岁，高脂血症。治疗前总胆固醇(TC)为6.31mmol/L，甘油三脂(TG)为2.16mmol/L。服用本发明组合物后两周，总胆固醇(TC)降为4.92mmol/L，甘油三脂(TG)降为0.99mmol/L。
(2)徐某，女，69岁，高脂血症。治疗前总胆固醇(TC)为5.79mmol/L，甘油三脂(TG)为4.12mmol/L。服用本发明组合物后两周，总胆固醇(TC)降为5.46mmol/L，甘油三脂(TG)降为1.50mmol/L。
Claims (17)
1.一种降血脂组合物，其特征在于，所述组合物由鸟氨酸、门冬氨酸、维生素B6、维生素C，以及下列辅助成分中的一种或几种组成：
枸橼酸、泛酸、生物素、叶酸；
其中，按重量比计：
鸟氨酸：门冬氨酸：维生素B6＝1：0.1~1.2：0.2~1.5；
鸟氨酸：维生素C＝1：0.05~1.2；
鸟氨酸：枸橼酸＝1：0.001~0.05；
鸟氨酸：泛酸＝1：0.00001~0.001；
鸟氨酸：生物素＝1：0.000001~0.0005；
鸟氨酸：叶酸＝1：0.000001~0.0005。
2.根据权利要求1所述的组合物，其特征在于所述组合物含有下列重量比的组分：
鸟氨酸：门冬氨酸：维生素B6＝1：0.3~0.7：0.4~0.8。
3.根据权利要求2所述的组合物，其特征在于所述组合物含有下列重量比的组分：
鸟氨酸：门冬氨酸：维生素B6＝1：0.5：0.6。
4.根据权利要求1所述的组合物，其特征在于所述组合物含有下列重量比的组分：
鸟氨酸：维生素C＝1：0.2~0.8。
5.根据权利要求4所述的组合物，其特征在于所述组合物含有下列重量比的组分：
鸟氨酸：维生素C＝1：0.5。
6.根据权利要求1所述的组合物，其特征在于所述组合物含有下列重量比的组分：
鸟氨酸：枸橼酸＝1：0.001~0.03。
7.根据权利要求6所述的组合物，其特征在于所述组合物含有下列重量比的组分：
鸟氨酸：枸橼酸＝1：0.01。
8.根据权利要求1所述的组合物，其特征在于所述组合物含有下列重量比的组分：
鸟氨酸：泛酸＝1：0.00005~0.0008。
9.根据权利要求8所述的组合物，其特征在于所述组合物含有下列重量比的组分：
鸟氨酸：泛酸＝1：0.0005。
10.根据权利要求1所述的组合物，其特征在于所述组合物含有下列重量比的组分：
鸟氨酸：生物素＝1：0.000001~0.0001。
11.根据权利要求10所述的组合物，其特征在于所述组合物含有下列重量比的组分：
鸟氨酸：生物素＝1：0.000003。
12.根据权利要求1所述的组合物，其特征在于所述组合物含有下列重量比的组分：
鸟氨酸：叶酸＝1：0.000003~0.0001。
13.根据权利要求12所述的组合物，其特征在于所述组合物含有下列重量比的组分：
鸟氨酸：叶酸＝1：0.00005。
14.根据权利要求1-13任一所述的组合物，其特征在于鸟氨酸是指L-鸟氨酸、D-鸟氨酸或者DL-鸟氨酸；门冬氨酸是指L-门冬氨酸、D-门冬氨酸或者DL-门冬氨酸。
15.权利要求1~13所述的任一组合物，其特征在于该组合物为保健品或药物时的剂型为药剂学上允许的任何一种剂型。
16.根据权利要求15所述的组合物，其特征在于剂型为：颗粒剂、片剂、胶囊剂、散剂、丸剂、粉剂、酒剂、膏剂、丹剂、冲剂、膜剂、口服液、注射剂。
17.权利要求1~13所述的任一组合物在制备降血脂的保健品、药物、食品或食品添加剂中的应用。
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410315242.XA CN104055773B (zh) | 2014-07-03 | 2014-07-03 | 一种降血脂组合物及其应用 |
| EP15815344.5A EP3165221B1 (en) | 2014-07-03 | 2015-07-02 | Blood-fat reducing composition and application thereof |
| ES15815344T ES2861023T3 (es) | 2014-07-03 | 2015-07-02 | Composición reductora de grasa en la sangre y aplicación de la misma |
| PCT/CN2015/083178 WO2016000637A1 (zh) | 2014-07-03 | 2015-07-02 | 一种降血脂组合物及其应用 |
| US15/551,031 US20180028543A1 (en) | 2014-07-03 | 2015-07-02 | Hypolipidemic composition and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410315242.XA CN104055773B (zh) | 2014-07-03 | 2014-07-03 | 一种降血脂组合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104055773A CN104055773A (zh) | 2014-09-24 |
| CN104055773B true CN104055773B (zh) | 2016-05-25 |
Family
ID=51543893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410315242.XA Active CN104055773B (zh) | 2014-07-03 | 2014-07-03 | 一种降血脂组合物及其应用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20180028543A1 (zh) |
| EP (1) | EP3165221B1 (zh) |
| CN (1) | CN104055773B (zh) |
| ES (1) | ES2861023T3 (zh) |
| WO (1) | WO2016000637A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104055773B (zh) * | 2014-07-03 | 2016-05-25 | 万红贵 | 一种降血脂组合物及其应用 |
| ES2699722B1 (es) * | 2015-12-21 | 2020-01-02 | Nanjing Jianrong Bio Tech Co Ltd | Composicion para tratar enfermedades de las neuronas motoras y uso de la misma |
| CN112915075A (zh) * | 2021-03-05 | 2021-06-08 | 中山大学 | 天门冬氨酸在预防或治疗肥胖症中的应用 |
| CN113350453B (zh) * | 2021-06-16 | 2022-08-26 | 广州市赛普特医药科技股份有限公司 | 用于升高hdl-c的组合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019888A (zh) * | 2006-12-28 | 2007-08-22 | 银小龙 | 治疗脂肪肝、酒精肝,降血脂、降转氨酶的药物 |
| CN101953825A (zh) * | 2010-09-25 | 2011-01-26 | 万红贵 | 一种解酒组合物及其在制备保健品中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20022358A1 (it) * | 2002-11-07 | 2004-05-08 | Bsd Bioscience Dev Snc | Composizioni farmaceutiche effervescenti per la realizzazione di sospensioni non convenzionali. |
| EP2163252A4 (en) * | 2007-05-17 | 2012-01-11 | Kaneka Corp | COMPOSITION CONTAINING A POLYPHENOL DERIVED FROM THE LICENSE |
| CN102772407B (zh) * | 2012-08-01 | 2014-09-17 | 岳茂兴 | 一种促进神经损伤修复的药物组合物及其应用 |
| WO2014139469A1 (en) * | 2013-03-15 | 2014-09-18 | Wuhan Qr Science And Technology Development Co. | Ornithine- or aspartate-containing compositions and the uses thereof |
| CN104055773B (zh) * | 2014-07-03 | 2016-05-25 | 万红贵 | 一种降血脂组合物及其应用 |
-
2014
- 2014-07-03 CN CN201410315242.XA patent/CN104055773B/zh active Active
-
2015
- 2015-07-02 ES ES15815344T patent/ES2861023T3/es active Active
- 2015-07-02 WO PCT/CN2015/083178 patent/WO2016000637A1/zh active Application Filing
- 2015-07-02 EP EP15815344.5A patent/EP3165221B1/en active Active
- 2015-07-02 US US15/551,031 patent/US20180028543A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019888A (zh) * | 2006-12-28 | 2007-08-22 | 银小龙 | 治疗脂肪肝、酒精肝,降血脂、降转氨酶的药物 |
| CN101953825A (zh) * | 2010-09-25 | 2011-01-26 | 万红贵 | 一种解酒组合物及其在制备保健品中的应用 |
Non-Patent Citations (2)
| Title |
|---|
| 左旋门冬氨酸鸟氨酸治疗非酒精性脂肪性肝炎的临床观察;尹合坤等;《中华全科医师杂志》;20040531;第3卷(第3期);173-175 * |
| 维生素B6对家兔实验性动脉粥状硬化的影响;梁效梅等;《中国动脉硬化杂志》;19951231;第3卷(第1期);53-55 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2861023T3 (es) | 2021-10-05 |
| CN104055773A (zh) | 2014-09-24 |
| EP3165221B1 (en) | 2020-12-30 |
| EP3165221A1 (en) | 2017-05-10 |
| EP3165221A4 (en) | 2018-03-14 |
| US20180028543A1 (en) | 2018-02-01 |
| WO2016000637A1 (zh) | 2016-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4699901B2 (ja) | 体脂肪代謝機能と燃焼エネルギーの活用機能とを備えているダイエット用添加物質 | |
| CN102355898B (zh) | 能量消耗促进剂 | |
| CN1329030C (zh) | 肝癌发生·发展抑制剂 | |
| JP5112865B2 (ja) | ヘモグロビン尿症またはミオグロビン尿症の予防または治療用組成物 | |
| WO2011077800A1 (ja) | 高脂血症改善剤、並びに、貧血改善組成物、尿酸値低下組成物及び飲食品 | |
| CN104055773B (zh) | 一种降血脂组合物及其应用 | |
| CN107580496B (zh) | 绞股蓝皂苷75的抗糖尿效果 | |
| US20210260015A1 (en) | Composition for inhibiting fat accumulation | |
| CN104411305A (zh) | 用于改善葡萄糖耐受的β-羟基-β-甲基丁酸 | |
| JP2009286703A (ja) | Ｄ−タガトースを有効成分とする体脂肪蓄積改善剤およびメタボリックシンドローム改善剤 | |
| JP2007161642A (ja) | アルコール性肝障害抑制剤 | |
| JPH09124473A (ja) | 体力増強剤 | |
| JP2010222284A (ja) | 血中ｇｉｐ上昇抑制剤 | |
| JP6143294B2 (ja) | 筋肉グリコーゲン回復時の筋肉グリコーゲン蓄積促進剤、及び筋肉グリコーゲン回復時の筋肉グリコーゲン蓄積促進用飲食品、並びに筋肉グリコーゲン回復時の筋肉グリコーゲン蓄積促進剤の製造方法 | |
| JP2007230987A (ja) | 抗肥満剤 | |
| KR101660834B1 (ko) | 지페노사이드 75의 항당뇨 효과 | |
| CN106349318A (zh) | 一种五环三萜化合物在制备治疗肥胖症药物中的应用 | |
| CN107809916A (zh) | 用于治疗营养不良的组合物和方法 | |
| Jenzer et al. | Essentials of Bioaccessibility and Bioavailability for Applied Nutritional Practices | |
| CN108991358A (zh) | 一种辅助降血脂、降血糖、缓解痛风保健食品及生产方法 | |
| JP2019162055A (ja) | エネルギー代謝促進用組成物 | |
| US11452704B2 (en) | Prevention and treatment of muscle wasting with ketone supplementation | |
| KR20110131140A (ko) | 오미자 효소의 호르몬 치유와 프로테인 식이요법 | |
| KR20220000029A (ko) | 면역력 증강을 위한 건강 기능 식품 및 그 조성물 | |
| AU2022378926A1 (en) | Compositions and methods using an autophagy inducer to enhance intermittent fasting |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |